Tempus AI, Inc. (TEM) shares climbed 9.7% to $79.21 as of November 2, 2026, a significant gain from the prior close of $72.22. BestStocks flagged the session as a major change for TEM. The move is tied to an earnings beat. Below, we break down what changed for TEM, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
Earnings Beat
Tempus AI, Inc. (TEM) reported EPS of $0.07 vs. consensus estimate of −$0.09, a beat of 179.9%. Monitor for confirmation of the earnings date and any revenue or guidance details that may accompany the full financial report.
This summary describes the catalyst and move as first detected on Nov 2, 2026, 10:08 AM EST; the stock has continued trading since, so the current price and percentage move (shown above) may be larger or smaller than the figures here.
Material / EarningsMedium confidence
Rel. volume
1.7×
Above Avg
Vs peers
—
No comparable peers
Market cap
$14.0B
NASDAQ
Analyst target
$73
-8.1% vs price
Price chart
Oct 2 – Nov 2
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details
What it means for Tempus AI, Inc. investors
For Tempus AI, Inc. investors, the balance of recent signals points to a bullish shift. On the constructive side: Earnings beat with positive market reaction; Strong 9.7% price move with conviction. Weighing against that: Tempus AI fell 6.11% to $76.90 despite announcing 13 abstracts accepted for presentation at the European Society for Medical Oncology Congress 2026 (Business Wire); Tempus AI, Inc. (TEM) moved -7.74% from $52.47 to $48.41 on 2026-07-20. Wall Street's consensus price target sits at $72.80, implying -8.1% downside from $79.21. Over the past 90 days analysts logged 1 upgrade and 0 downgrades. BestStocks rates the overall signal quality medium (79/100). With earnings roughly 113 days out, the next report is the most likely near-term test of the move.
TEM price reaction
TEM last traded at $79.21, up $6.99 (+9.68%) from the previous close of $72.22. The session traded on 1.7× average volume (above avg), so the move carried above-average conviction. Over the past month the stock has ranged between $63.81 and $83.55, and it currently sits about 78% of the way up that band.
Bullish and bearish analyst opinions on Tempus AI, Inc. (TEM)
▲Latest catalyst·strengthens the bull case
The latest catalyst — an earnings beat the market rewarded — it strengthens the bull case.
The consensus analyst price target on Tempus AI, Inc. (TEM) is $72.80, 8.1% below the recent $79.21. Over the past 90 days analysts logged 1 upgrade, 11 maintains, and 0 downgrades. Here is how the bullish and bearish cases on TEM line up.
▲ The bullish case
+The Street's most bullish target is $92.00 (+16.1%).
+1 analyst upgrade in the past 90 days, most recently Piper Sandler to Overweight (2026-09-01).
+Earnings beat with positive market reaction.
+Strong 9.7% price move with conviction.
+Tempus AI reported third-quarter 2026 results today, with revenue from its cancer screening business rising 23% year-over-year, per Business Wire and Barron's coverage.
▼ The bearish case
−The consensus analyst price target of $72.80 sits 8.1% below the recent $79.21, so the average target sees limited room to run.
−The most bearish analyst target is $50.00 (-36.9%).
−Tempus AI fell 6.11% to $76.90 despite announcing 13 abstracts accepted for presentation at the European Society for Medical Oncology Congress 2026 (Business Wire).
−Tempus AI, Inc. (TEM) moved -7.74% from $52.47 to $48.41 on 2026-07-20.
Bull vs bear balanceBullish Shift
BearishNeutralBullish
The latest catalyst moved the balance toward the bulls — the hollow tick marks where it sat before.
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Nov 2, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Tempus AI reported third-quarter 2026 results today, with revenue from its cancer screening business rising 23% year-over-year, per Business Wire and Barron's coverage. The stock climbed 8.58% to $78.42 on elevated volume (4.63x expected at this session point), reflecting investor appetite for the company's core oncology diagnostics momentum.
Tempus AI shares rose 6.49% to $76.83, driven by a combination of positive catalysts including EU IVDR Class C certification for its xR RNA-sequencing assay for solid-tumor genomic profiling and a multi-year oncology data and software collaboration expected to generate substantial multi-million-dollar cash payments, according to the web catalyst summary. Anticipation of the November 2 earnings report and reaffirmed analyst support (BTIG maintaining Buy with an $80 price target) added to momentum. Volume at 3.44 million shares ran 1.14x normal for this time of session.
Tempus AI rose 6.02% to $71.20, gaining $4.04 from a $67.16 open. The move comes two trading days ahead of the company's November 2 earnings report, which 247wallst.com flagged as carrying a '$1.5 Billion Question' for investors. Volume stands at 1.83M shares (0.76x the historical average at this point in the session), indicating typical intraday participation.
Tempus AI, Inc. moved +6.25% intraday from $63.81 to $67.80. Seeking Alpha: Tempus AI: Moderna's New Cancer Vaccine Partner Is The Pick Of The AI Biotech Bunch
Tempus AI rose 6.99% to $68.84 following positive clinical data on AI-enabled pre-screening tools for non-small cell lung cancer patient identification, combined with recent analyst upgrades from JPMorgan Chase and Piper Sandler that raised price targets, per web sources cited by Yahoo Finance. Volume of 2.6M shares ran 51% below the time-adjusted historical average, suggesting the move occurred on lighter participation.
Material / Earnings2026-10-06-13.8%
Tempus AI, Inc. (TEM) moved -15.28% from $84.97 to $71.98 on 2026-10-06 on volume 2.6x the 5-day average. We checked news, earnings, analyst updates, filings, and corporate actions. The only company-specific event found was an announcement that Tempus AI launched FDA-cleared AI-ECG tools to expand its cardiovascular diagnostic portfolio—a product expansion, not an earnings miss or negative catalyst.
Tempus AI rose 6.47% to $81.59, driven by positive market focus on its expanding cardiovascular portfolio and recent FDA clearances for diagnostic AI products, particularly its ECG-PH offering. The web catalyst cited regulatory momentum and strategic positioning within the AI-ECG market, forecasted to reach $2.40 billion in 2026 with 19.3% CAGR. Volume of 2.82M shares was 1.13x the session-adjusted average, reflecting normal trading activity.
Tempus AI fell 6.11% to $76.90 despite announcing 13 abstracts accepted for presentation at the European Society for Medical Oncology Congress 2026 (Business Wire). The decline occurred on volume 0.98x the expected daily average, suggesting the positive research milestone did not offset broader selling pressure or profit-taking in the session.
In-depth TEM event analyses
Permanent, dated analyses of TEM's most significant sessions.
TEM climbed 9.7% to $79.21. The move is associated with an earnings beat.
How much did TEM stock rise?
TEM gained 9.68% ($6.99) versus the prior close of $72.22, last trading at $79.21 on 1.7× average volume.
When is Tempus AI, Inc.'s next earnings date?
TEM's next earnings report is estimated for 2027-02-23 — about 113 days away.
What is the analyst price target for TEM?
The consensus analyst price target for TEM is $72.80, about 8.1% below the current $79.21. Over the past 90 days, analysts recorded 1 upgrade, 11 maintains, and 0 downgrades.
How BestStocks tracks TEM
This page is generated automatically by BestStocks' change-detection system after an earnings beat was detected and verified against independent data sources. It draws on 20 tracked change events for TEM, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 2, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
